Number of the records: 1
afatinib
SYS d000077716 LBL 00000nz--a2200181n--4500 005 20250606222654.6 008 190101|||anznnbabn-----------|-a|a------ 040 $b slo $a BA006 $d BA006 065 $a D02.065.132 065 $a D03.633.100.786.188 066 $a 01 $c 03 150 $a afatinib $x AA $x AD $x AE $x AG $x AI $x AN $x BL $x CF $x CH $x CL $x CS $x EC $x HI $x IM $x IP $x ME $x PD $x PK $x PO $x RE $x SD $x ST $x TO $x TU $x UR $2 slo 450 $w v $a afatinib dimaleát $2 slo 450 $w v $a afatinib maleát $2 slo 450 $w v $a Gilotrif $2 slo 550 $7 sllk_us_auth*d000970 $Y Antineoplastic Agents $w P $a antineoplastiká 550 $7 sllk_us_auth*d000092004 $Y Tyrosine Kinase Inhibitors $w P $a inhibítory tyrozínkináz 665 $a 2019 (2007) $2 eng 680 9-
$i A quinazoline and butenamide derivative that acts as a tyrosine kinase inhibitor of epidermal growth factor receptors (ERBB RECEPTORS) and is used in the treatment of metastatic NON-SMALL CELL LUNG CANCER. $2 eng 750 -2
$a Afatinib $2 eng 980 $x M
Number of the records: 1